TIMP3
TIMP3 (TIMP metallopeptidase inhibitor 3, also known as metalloproteinase inhibitor 3 or SFD) is a secreted protein of the extracellular matrix that reversibly inhibits matrix metalloproteinases and other zinc proteases. It contributes to matrix turnover, inflammation and angiogenesis. Browse Assay Genie's current range of TIMP3 research reagents below, or read on for the biology behind the target.
TIMP3 mediates matrix regulation and turnover, inflammation and angiogenesis through reversible inhibition of zinc protease superfamily enzymes, chiefly matrix metalloproteinases (MMPs). It regulates extracellular matrix (ECM) remodelling by inhibiting MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15. It also modulates the processing of amyloid precursor protein (APP) and the apolipoprotein E receptor ApoER2 by inhibiting the alpha-secretases ADAM10 and ADAM17.
Beyond protease inhibition, TIMP3 functions as a tumour suppressor and a potent inhibitor of angiogenesis. It interacts directly with VEGF receptor-2 (KDR) and prevents VEGFA from binding to it. It selectively induces apoptosis in angiogenic endothelial cells through a caspase-independent pathway. Mechanistically, it inhibits matrix-induced tyrosine phosphorylation of focal adhesion kinase (PTK2) and its association with paxillin (PXN), and it disrupts the incorporation of ITGB3, PTK2 and PXN into focal adhesion contacts on the matrix.
The TIMP3 gene belongs to the TIMP gene family, and the protein belongs to the protease inhibitor I35 (TIMP) family. It is a netrin domain-containing protein localised to the ECM, and its expression is induced in response to mitogenic stimulation. Mutations in the TIMP3 gene are associated with Sorsby's fundus dystrophy, an autosomal dominant disorder, which is the origin of the alias SFD and of the earlier name tissue inhibitor of metalloproteinase 3. Mouse and rat both have a Timp3 ortholog.
TIMP3 inhibits a broad set of MMPs, making it a key regulator of matrix regulation and turnover.
TIMP3 blocks VEGFA binding to KDR and induces apoptosis in angiogenic endothelial cells.
TIMP3 is described as a tumour suppressor, linking protease inhibition and anti-angiogenic activity to tumour studies.
TIMP3 mutations cause Sorsby's fundus dystrophy, and TIMP3 modulates APP processing through ADAM10 and ADAM17.
TIMP3 reversibly inhibits zinc proteases, mainly matrix metalloproteinases, and so regulates ECM remodelling. It also inhibits ADAM10 and ADAM17, and acts as an anti-angiogenic tumour suppressor by preventing VEGFA binding to VEGF receptor-2 (KDR).
The HGNC name is TIMP metallopeptidase inhibitor 3, and UniProt lists metalloproteinase inhibitor 3. The alias SFD and the earlier name tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) reflect the link to Sorsby's fundus dystrophy.
Mutations in TIMP3 are associated with autosomal dominant Sorsby's fundus dystrophy. Orthologs named Timp3 exist in mouse and rat, so rodent models can be used; check the datasheet of any product for its validated reactivity.
Other members of the TIMP family of tissue inhibitors of metallopeptidases with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P35625; product specifications from Assay Genie datasheets.